Implications for novel growth factor therapies in diabetic retinopathy

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 4, 1996, Pages 307-314

  Aiello, Lloyd Paul ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013626833     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199608000-00005     Document Type: Article

References (74)

1. Patz A: Studies on retinal neovascularization. Invest Ophthalmol Vis Sci 1980, 19:1133-1138.
2. National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1994.
3. Klein HA, Moorehead HB: Statistics on Blindness in the Model Reporting Area, 1969-1970. [DHEW publication no. (NIH) 73-427]; 1970.
4. Klein R, Klein BEK: Vision disorders in diabetes. In National Diabetes Data Group: Diabetes in America: Diabetes Data Compiled 1984. [NIH publication no. 85-1468.]
5. Javitt JC, Aiello LP, Bassi LJ: Detecting and treating retinopathy in patients with type 1 diabetes mellitus. Ophthalmology 1991, 98:1565-1574.
6. Javitt JC, Aiello LP, Chiang YP: Preventive eye care in people with diabetes is cost saving to the federal government. Diabetes Care 1994, 17:909-917.
7. Diabetic Retinopathy Study Report Number 2: Photocoagulation of proliferative diabetic retinopathy. Ophthalmology 1978, 85:82.
8. Early Treatment Diabetic Retinopathy Study Report Number 9: Early photocoagulation for diabetic retinopathy. Ophthalmology 1991, 98:766-785.
9. Michaelson IC: The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal disease. Trans Br Ophthalmol Soc 1948, 68:137-180.
10. Gartner S, Henkind P: Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol 1978, 22:291-312.
11. Henkind P: Ocular neovascularization. Am J Ophthalmol 1978, 85:287-301.
12. Branch Vein Occlusion Study Group: Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. Arch Ophthalmol 1986, 104:34-41.
13. Aiello L, Wand M, Liang G: Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. Ophthalmology 1983, 90:814-820.
14. Ashton N. Retinal vascularization in health and disease. Am J Ophthalmol 1957, 44:7-24.
15. Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Ann Rev Biochem 1989, 58:575-606.
16. Vlodavsky K, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, Klagsbrun M: Endothellal cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A 1987, 84:2292-2296.
17. Montesano R, Vassali JD, Baird A, Guillemin R, Orci L: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A 1986, 83:7297-7301.
18. Shing Y, Folkman J, Haudenschild C, Lund D, Crum R, Klagsbrun M: Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 1985, 29:275-287.
19. Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA, Gospodarowicz D, Fiddes JC: Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986, 233:545-548.
20. Kandel J, Bossy-Wetzel E, Radvany F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66:1095-1104.
21. McNeil PL, Muthukrishnan L, Warder ME, D'Amore PA: Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989, 109:811-822.
22. Gao H, Hollyfield JG: Basic fibroblast growth factor (bFGF) immunolocalization in the rodent outer retina demonstrated with an anti-rodent bFGF antibody. Brain Res 1992, 585:355-3601.
23. Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L: Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990, 108:869-872.
24. Poulsen JE: The Houssay phenomenon in man. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953, 2:7-12.
25. Poulsen J: Diabetes and anterior pituitary insufficiency. Final course and postmortem study of a diabetic patient with Sheehan's syndrome. Diabetes 1966, 15:73-77.
26. Sharp P, Fallon T, Brazier O, Sandler L, Joplin G, Kohner E: Long-term follow-up of patients who underwent Yttrium-90 pituitary implantation for treatment of proliferate diabetic retinopathy. Diabetologia 1987, 30:199-207.
27. Merimee T: A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N Engl J Med 1978, 298:1217-1222.
28. LeRoith D, Roberts CT Jr: Insulin-like growth factors. Ann N Y Acad Sci 1993, 692:1-9.
29. Grant MB, Guay C, Marsh R: Insulin-like growth factor I stimulates proliferation, migration and plasminogen activator release by human retinal pigment epithelial cells. Curr Eye Res 1990, 9:323-335.
30. Grant MB, Mames RN, Fitgerald C, Ellis EA, Caballero S, Chegini N, Guy J: Insulin-like growth factor I as an angiogenic agent in vivo and in vitro studies. Ann N Y Acad Sci 1993, 692:230-242.
31. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak JF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
32. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1312.
33. Leung DW, Cachianes G, Kunang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
34. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991, 47:211-218.
35. Senger D, Connolly D, Van De Water L, Feder J, Dvorak H: Purification and NH2-terminal amino acid sequence of guinea pig tumor secreted vascular permeability factor. Cancer Res 1990, 50:1774-1778.
36. Brock T, Dvorak H, Senger D: Tumor secreted vascular permeability factor increases cytosolic Ca++ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991, 138:213-221.
37. Pepper M, Ferrara N, Orci L, Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Comm 1992, 189:824-831.
38. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
39. Ferrara N, Houck K, Jakeman L, Leung D: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992, 13:18-32.
40. Guerrin M, Moukadiri H, Chollet P, Moro F, Dutt K, Malecaze F, Plouet J: Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995, 164:385-394. The first demonstration that VEGF is mitogenic for ocular cell types other than endothelial cells. Two high-affinity VEGF receptors were found on retinal pigment epithelial cells and their proliferation and migration were induced by VEGF.
41. Takagi H, King GL, Aiello LP: Identification and characterization of vascular endothelial growth factor receptor (fit) in bovine retinal pericytes. Diabetes 1996, in press. Characterization of VEGF receptors on retinal pericytes, an ocular cell of non-endothelial origin. Although VEGF-induced pericyte growth was limited and delayed, tyrosine phosphorylation of several intracellular molecules was noted, suggesting that VEGF may mediate those effects in retinal pericytes that are as yet unidentified.
42. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J, Yamamoto H: Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995, 270:28316-28324. The first description of VEGF receptors on retinal pericytes in which only Flt1 mRNA was observed in contrast with the usual two classes of VEGF receptor (Flk and Flt) found on endothelial cells.
43. Kim KJ, Li B, Winer J, Armanini M, Gillette N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362:841-844.
44. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
45. McGookin E, Stopa E, Kuo-LeBlanc, Baird A, Gonzalez A, Hanneken A, Streeten B: Vascular endothelial growth factor (VEQF) has a different distribution than basic fibroblast growth factor (bFGF) in the adult human retina [abstract]. Invest Ophthalmol Vis Sci 1992, 33:651.
46. Adamis AP, Shima DT, Yeo K-T, Yeo T-K, Brown LF, Berse B, D'Amore PA, Folkman J: Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993, 193:631-638.
47. Aiello L, Northrup J, Keyt B, Takagi H, Iwamoto M: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995, 113:1538-1544. An evaluation of the hypoxic regulation of three ocular cell types, including endothelial cells, pericytes, and pigment epithelial cells. Hypoxia induced VEGF expression in all cells in a dose-dependent and reversible manner. Endothelial cell growth was stimulated by exogenous VEGF and by media conditioned under hypoxic conditions by ocular cells. VEGF-neutralizing compounds eliminated both of these responses, suggesting VEGF was the primary hypoxia-induced mitogen under these conditions.
48. Yang Q, Zwijsen A, Slegers H, Vanden Berghe D: Purification and characterization of VEGF/VPF secreted by human retinal pigment epithelial cells. Endothelium 1994, 2:73-85.
49. Simorre P, Guerrin M, Chollet P, Penary M, Clamens S, Malecaze F, Plouet J: Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci 1994, 35:3393-3400.
50. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL: Comparative analysis of vascular endothelial growth factor (VEGF) receptors on retinal and aortic microvascular endothelial cells. Diabetes 1994, 44:98-103.
51. Smith L, Wesolowski E, McLellan A, Kostyk S, D'Amato R, Sullivan R: Oxygen-induced retlnopathy in the mouse. Invest Ophthalmol Vis Sci 1994, 35:101-111.
52. Pierce EA, Avery R, Foley E, Aiello L, Smith LEH: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 1995, 92:905-909. This study demonstrated that VEGF expression was correlated both temporally and spatially with the onset of ischemia-induced retinal neovascularization in the mouse. Protein localization predominated at Muller-like cells, but mRNA expression was primarily found in the inner nuclear retinal layers.
53. Miller JW, Adamis AP, Shima D, D'Amore PA, Moulton R, O'Reilly M, Folkman J, Brown L, Berse B, Yeo T-K, Yeo K-T: Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994, 145:574-584.
54. Stone J, Chang-Ling T, Pe're J, Itin A, Gnessin H, Keshet E: Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996, 37:290-299. A careful study detailing the sequential role of various ocular cell types, hypoxia, and VEGF in the developing cat and rat retina. Hypoxic regulation of VEGF expression in the intact developing retina was demonstrated by using oxygen-enriched atmospheres that inhibited vessel formation and endogenous VEGF production.
55. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H: Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995, 27:48-52. The first indirect evidence that VEGF may play a role in diabetic retinal hyperpermeability; VEGF protein expression and serum albumin extravasation were colocalized using immunohistochemistry in diabetic rats. As compared with control retinas, VEGF expression was increased in diabetic retinas.
56. Duh E, Aiello LP, Takagi C, Clermont A, Mori F, King GL, Bursell SE: Vascular endothelial growth factor (VEGF) increases retinal vascular permeability in vivo, [abstract]. Ophthalmol Vis Sci 1996, 37:121.
57. Grant M, Russell B, Fitgerald C, Merimee TJ: Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes 1986, 35:416-420.
58. Dills DG, Moss SE, Klein R, Klein BEK: Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes. Diabetes 1991, 40:1725-1730.
59. Wang Q, Dills DG, Klein R, Klein BEK, Moss SE: Does insulin-like growth factor 1 predict incidence and progression of diabetic retinopathy? Diabetes 1995, 44:161-164. A carefully performed and detailed evaluation of serum IGF-1 levels and incidence of retinopathy over a 6-year period in a well-characterized cohort of more than 1000 individuals. No correlation between IGF-1 and incidence or progression of retinopathy was found in any subgroup.
60. Aiello LP, Avery RL, Arrigg PG, Keyt B, Aiello LM, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Ferrara N, King GL: Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331:1480-1487. Evaluation of 210 intraocular fluid samples from 164 patients (143 from diabetic individuals) demonstrated that both aqueous and vitreous VEGF concentrations were high during active intraocular neovascularization and low at other times. The predicted intraocular concentration gradient and VEGF reduction following successful treatment with laser photocoagulation were also demonstrated.
61. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo T-K, Yeo K-T: Elevated vascular permeability factor/vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118:445-450.
62. Malecaze F, Clamens S, Simorre-Pinatel V, Chollet P, Favard C, Bayard F, Plouet J: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994, 112:1476-1482. A survey of eight growth factors in neovascular membranes obtained from diabetic patients; using polymerase chain reaction technology, only VEGF was detected in all samples.
63. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, KE: Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularization ocular diseases. Lab Invest 1995, 72:638-645.
64. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH: Inhibition of vascular endothelial growth factor suppresses retinal neovascularization in vivo. Proc Natl Acad Sci U S A 1995, 92:10457-10461. Injections of VEGF-neutralizing receptor chimeric proteins were given intravitreally in a murine model of ischemia-induced retinal neovascularization. Retinal neovascularization was suppressed in 95% to 100% of animals evaluated. The inhibition was dose dependent and occurred without detectable toxicity by light microscopic evaluation.
65. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LEH: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 1996, 93:4851-4856. In the same murine model as described by Aiello et al. (Proc Natl Acad Sci U S A 1995, 92:10457-10461). VEGF antisense phosphorothioate oligodeoxynucleotides were shown to reduce VEGF protein expression in a dose-dependent manner, resulting in reduction of retinal neovascularization.
66. Adamis A, Shima D, Tolentino M, Gragoudas E, Ferrara N, Folkman J, D'Amore P, Miller J: Inhibition of VEGF prevents ocular neovascularization in a nonhuman primate. Arch Ophthalmol 1996, 114:66-71. Iris neovascularization due to iatrogenically induced retinal vein occlusion in the primate was inhibited by intraocular injection every other day of VEGF-neutralizing antibodies. Hypoxic induction of VEGF mRNA was not inhibited.
67. Bontemps F, Mimouni M, Van den Berghe G: Mechanisms of elevation of adenosine levels in anoxic hepatocytes. J Biochem 1993, 290:671-677.
68. Collis MG, Hourani SMO: Adenosine receptor subtypes. Tips Rev 1993, 14:360-366.
69. Hashimoto E, Kage K, Ogita T, Nakaoka T, Matsuoka R, Kira Y: Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. Biochem Biophys Res Commun 1994, 204:318-324.
70. 2 receptors on retinal microvascular endothelial cells.
71. Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP: Hypoxic-induction of vascular endothelial growth factor (VEGF) is mediated by adenosine, adennosine A2 receptors and cAMP-dependent protein kinase A in retinal microvascular pericytes and vascular endothelial cells. Invest Ophthalmol Vis Sci 1996, in press.
72. Guo D, Jia Q, Song HY, Warren RS, Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains in association with endothelial cell proliferation. J Biol Chem 1994, 270:6729-6733.
73. Waltenberger J, Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269:26988-26995.
74. Aiello LP, Pu X, Zhen ZY, Park DJ, Newsome WP, King GL: Vascular endothelial growth factor (VEGF) activation of phospholipase Cγ, P13-kinase & PKC pathways and their effects on endothelial cell proliferation. Invest Ophthalmol Vis Sci 1996, 37:204.